These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 29304144)
1. A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. Davis CL; Wahid R; Toapanta FR; Simon JK; Sztein MB PLoS One; 2018; 13(1):e0189571. PubMed ID: 29304144 [TBL] [Abstract][Full Text] [Related]
2. Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics. Davis CL; Wahid R; Toapanta FR; Simon JK; Sztein MB; Levy D PLoS One; 2013; 8(4):e59465. PubMed ID: 23589755 [TBL] [Abstract][Full Text] [Related]
3. Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development. Mani S; Toapanta FR; McArthur MA; Qadri F; Svennerholm AM; Devriendt B; Phalipon A; Cohen D; Sztein MB Vaccine; 2019 Aug; 37(34):4787-4793. PubMed ID: 31230883 [TBL] [Abstract][Full Text] [Related]
4. How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella? Giersing BK; Porter CK; Kotloff K; Neels P; Cravioto A; MacLennan CA Vaccine; 2019 Aug; 37(34):4778-4783. PubMed ID: 31358238 [TBL] [Abstract][Full Text] [Related]
5. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine. Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141 [TBL] [Abstract][Full Text] [Related]
6. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680 [TBL] [Abstract][Full Text] [Related]
10. Development of recombinant vaccine candidate molecule against Shigella infection. Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Levine MM; Kotloff KL; Barry EM; Pasetti MF; Sztein MB Nat Rev Microbiol; 2007 Jul; 5(7):540-53. PubMed ID: 17558427 [TBL] [Abstract][Full Text] [Related]
12. Classical and novel strategies to develop a Barel LA; Mulard LA Hum Vaccin Immunother; 2019; 15(6):1338-1356. PubMed ID: 31158047 [No Abstract] [Full Text] [Related]
13. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017 [TBL] [Abstract][Full Text] [Related]
14. Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Lu T; Das S; Howlader DR; Jain A; Hu G; Dietz ZK; Zheng Q; Ratnakaram SSK; Whittier SK; Varisco DJ; Ernst RK; Picking WD; Picking WL Front Immunol; 2023; 14():1194912. PubMed ID: 37744341 [TBL] [Abstract][Full Text] [Related]
15. Functional antibodies as immunological endpoints to evaluate protective immunity against Ndungo E; Pasetti MF Hum Vaccin Immunother; 2020; 16(1):197-205. PubMed ID: 31287754 [TBL] [Abstract][Full Text] [Related]
17. Heat killed multi-serotype Shigella immunogens induced humoral immunity and protection against heterologous challenge in rabbit model. Nag D; Sinha R; Mitra S; Barman S; Takeda Y; Shinoda S; Chakrabarti MK; Koley H Immunobiology; 2015 Nov; 220(11):1275-83. PubMed ID: 26210044 [TBL] [Abstract][Full Text] [Related]
18. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model. Yagnik B; Sharma D; Padh H; Desai P Vaccine; 2019 May; 37(23):3097-3105. PubMed ID: 31047673 [TBL] [Abstract][Full Text] [Related]
19. Progress and pitfalls in Shigella vaccine research. Barry EM; Pasetti MF; Sztein MB; Fasano A; Kotloff KL; Levine MM Nat Rev Gastroenterol Hepatol; 2013 Apr; 10(4):245-55. PubMed ID: 23419287 [TBL] [Abstract][Full Text] [Related]
20. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Barry E; Cassels F; Riddle M; Walker R; Wierzba T Vaccine; 2019 Aug; 37(34):4768-4774. PubMed ID: 31358236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]